Wren Laboratories
Wren Laboratories, a Yale University spinoff and a CLIA, CAP, and NYSDOH-licensed lab, is at the forefront of advancing precision medicine through cutting-edge mRNA liquid biopsy diagnostics. The company's mission is to transform cancer diagnostics and accelerate drug development by providing real-time, non-invasive insights into cancer. Their proprietary technology utilizes machine learning and multi-gene mRNA expression analysis to detect minimal residual disease, predict therapeutic responses, and improve patient prognosis. Wren offers clinically validated diagnostics such as NETest® for neuroendocrine tumors and PROSTest® for prostate cancer, with ongoing development for other cancers like colorectal, lung, and breast. They serve both clinicians and biopharma partners, offering support for drug discovery and companion diagnostic development. The company emphasizes its global reach, collaborating with over 45 medical institutions across 15 countries and holding over 115 patents with more than 60 clinical studies contributing to their research.
Wren Laboratories
Wren Laboratories, a Yale University spinoff and a CLIA, CAP, and NYSDOH-licensed lab, is at the forefront of advancing precision medicine through cutting-edge mRNA liquid biopsy diagnostics. The company's mission is to transform cancer diagnostics and accelerate drug development by providing real-time, non-invasive insights into cancer. Their proprietary technology utilizes machine learning and multi-gene mRNA expression analysis to detect minimal residual disease, predict therapeutic responses, and improve patient prognosis. Wren offers clinically validated diagnostics such as NETest® for neuroendocrine tumors and PROSTest® for prostate cancer, with ongoing development for other cancers like colorectal, lung, and breast. They serve both clinicians and biopharma partners, offering support for drug discovery and companion diagnostic development. The company emphasizes its global reach, collaborating with over 45 medical institutions across 15 countries and holding over 115 patents with more than 60 clinical studies contributing to their research.